52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), ...

YouTube video by Cure Melanoma

The Investor Relations website contains information about IOVANCE Biotherapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

26% Objective Response Rate  Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif....

Review abstracts, posters, presentations, and other publications.

This trial is enrolling people with non-small cell lung cancer that has progressed on previous chemoimmunotherapy and is metastatic. See the eligibility criteria, what to expect and find a nearby tria...

On Feb 19, MRA's Meet-Up covered TIL therapy, the TILVANCE-301 trial, and a patient-physician duo’s insights on clinical trials and the future of melanoma treatment.

Rusty Konkol's metastatic melanoma, the most dangerous form of skin cancer, is being treated at Froedtert with a newly approved cancer drug.

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previousl...

Plus, Creative Mornings is launching an Indie Business Club for entrepreneurs looking for community.

Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Tota...

The Investor Relations website contains information about IOVANCE Biotherapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.